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a young woman presenting with abdominal pain, ascites, and
hepatomegaly; however, the clinical presentation varies.
Usually patients show an underlying prothrombotic disorder,
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Abstract: Due to its rarity, experience with pregnancy in Budd–Chiari
syndrome (BCS) is limited. With the advent of new treatment mod-
alities, transjugular intrahepatic portosystemic shunt in particular,
numbers of affected women seeking pregnancy with BCS are expected
to rise. Here, we use a case that ended lethal within 2 years after delivery
to discuss the effect of pregnancy on BCS and vice versa, and to
highlight the necessity of a multidisciplinary teamwork. Additionally, a
risk classification is proposed which may serve as a framework for
preconception counseling and assist in the establishment and evaluation
of treatment algorithms; its criteria need to be defined and assessed for
their applicability in further studies.
(Medicine 95(22):e3817)
Abbreviations: aXa = anti-Factor Xa, BCS = Budd–Chiari
Syndrome, ET = essential thrombocythemia, GA = gestational
age, HIT = heparin-induced thrombocytopenia, IPSET =
international prognostic score of thrombosis in World Health
Organization-essential thrombocythemia, IVC = inferior vena cava,
LMWH = low-molecular-weight heparin, LTX = orthotopic liver
transplantation, MELD = model for end-stage liver disease, NSE =
nonstandard exception, PNF = primary nonfunction, TIPS =
transjugular portosystemic shunt, VKA = vitamin K antagonists,
WHO = World Health Organization.
INTRODUCTION
B udd–Chiari syndrome (BCS) is defined as obstruction ofthe hepatic venous outflow. This obstruction might be
located anywhere between the small hepatic veins to the
suprahepatic inferior vena cava (IVC).1 The typical patient isD, Valeria Hippe, etzsch, Prof,
, Ulrich Gembruch, Prof, and Jonel Trebicka, Prof
and in a substantial number of patients several risk factors are
found.2 The disease is mainly diagnosed by imaging, whereas
therapeutic options comprise a step-wise approach with medi-
cation (anticoagulation), minimally invasive procedures such as
thrombolysis, percutaneous angioplasty, transjugular intrahe-
patic portosystemic shunting (TIPS), but also surgical porto-
systemic shunting, and orthotopic liver transplantation (LTX).
BCS is a rare disease but a clinical challenge. Moreover,
pregnancy in women with BCS is extremely rare; pregnancy
exerts a detrimental effect on the course of the disease. Here we
report the case of a patient with BCS due to essential thrombo-
cythemia (ET) and TIPS which ended lethal within 19 months
after delivery. The manuscript was written after the patient’s
death. The University Bonn Medical School Ethics committee
allows publication without consent in such cases. Additionally,
we propose a score for risk classification of pregnancy in
women with pre-existing BCS.
CASE
At the age of 16, essential thrombocythemia was diagnosed
(JAK2V617K negative). A stable course of disease could be
achieved for 8 years by treatment with hydroxyurea, when acute
BCS occurred with occlusion of all liver veins. Treatment
consisted of lysis and veno-venous shunt (Palmaz-stent) place-
ment between left hepatic vein and IVC at a regional hospital
(Figure 1) in conjunction with anticoagulant treatment using the
vitamin K-antagonist (VKA) phenprocoumon. She remained
stable for the subsequent 12 years with well-controlled hema-
tologic disease and without thrombotic or portal hypertensive
complications. At 36 years of age, progressive, recurrent ascites
developed which was treated by creating a new TIPS using a
baremetal and a covered stent.
This TIPS-tract was created from the ostium of the left
liver vein, very close to the end of the Palmaz-stent and the left
portal vein branch. The pressure gradient dropped >50%
(portosystemic gradient decrease from 36 to 15 mm Hg, see
Figure 1A), as usual during TIPS insertion.3–5 In the follow-up
visits, the TIPS was patent and there was no need for invasive
measurements until the patient conceived. One year after TIPS
revision, at the age of 38, the patient conceived. During
pregnancy, close interdisciplinary care was established. VKA
anticoagulation was replaced by therapeutic dose of the low-
molecular-weight heparin (LMWH) enoxaparin with regular
monitoring of anti-FXa (aXa) activity (peak aXa-level: 1.0 –
1.2 U/mL), and hydroxyurea was discontinued due to its ter-
atogeneity. Even though the recommendation in patients with
high-risk ET is to use interferon-alpha (evidence level III and
Grade B), we advised against it, as there are no controlled
studies which show a clear benefit regarding teratogeneity, and,o experience in the situation of BCS.6
amined 4-weekly using Doppler-ultra-
s of ascites were first detected at a
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Merz et al Medicine  Volume 95, Number 22, June 2016gestational age (GA) of 12 weeks. First- and second-trimester
ultrasound examinations including echocardiography and Dop-
pler examination of the fetal and uterine vessels were unre-
markable. Platelet numbers were within the upper normal range
(500–680 G/L). Despite aXa-adjusted anticoagulation within
the therapeutic range (enoxaparin 60 mg qam, 80 mg qhs),
thrombosis of the right subclavian vein occurred at GA 25.
Therefore, testing for heparin-induced thrombocytopenia
(HIT) typical antibodies was performed, and medication was
changed to fondaparinux (5 mg bd), as the anticoagulant and
antithrombotic efficacy of fondaparinux at this dosage is superior.
A gradual deterioration of her general condition occurred; she
complained of increasing abdominal distension, pain, and dys-
pnea. Although TIPS was patent at every control, recurrent
paracenteses (overall volume 15.4 L) had to be performed to
relieve these symptoms. Serial ultrasound of the uterine cervix
revealed progressive shortening, prompting tocolytic therapy
with atosiban and administration of corticosteroids for accelera-
tion of fetal pulmonary maturity at 28 weeks of gestation. At GA
28þ 2, abnormal fetal heart rate tracings and progressive cervical
dilatation necessitated cesarean delivery, which was performed
under general anesthesia. Anticoagulation was switched to
unfractioned heparin for perioperative bridging. An apparently
healthy girl was born (1205 g, 64. percentile, Apgar 8/9/10,
arterial pH 7.34) and transferred to the neonatal intensive care
unit. The estimated blood loss was 400 mL. Operation and post-
operative surgical course was unremarkable; several litres of
ascites were drained after abdominal incision. The newborn had
to undergo emergency laparotomy on day 1 for gastric perfor-
ation. The further course was uncomplicated, and the baby was
discharged home 8 weeks later.
Post partum, ascites, and upper abdominal pain worsened
FIGURE 1. (A) Invasive portography after left-sided TIPS placeme
demonstrating cavernous transformed portal occlusion and restore
portal vein; (3) left hepatic vein. TIPS ¼ transjugular portosystemdespite continuous ascites drainage and medication. Upper
gastrointestinal endoscopy was therefore performed on post-
operative day 4, which revealed grade II esophageal and grade I
2 | www.md-journal.comgastric varices. Therefore, TIPS dysfunction was suspected.
Invasive TIPS-control demonstrated a foreshortening of the
uncovered stent at the portal segment with associated cavernous
transformed portal venous thrombosis. Subsequently, a covered
stent elongation to a big portal varice was performed (porto-
systemic gradient decreased from 12 to 6 mm Hg, see Figure 1B
and C). Thereafter, the patient was stable on treatment with
hydroxyurea and fondaparinux; the latter was switched to
rivaroxaban 2 weeks postpartum. Five months later TIPS
reocclusion was diagnosed (see Figure 2). This may have
occurred as a result of severe thrombocytosis (1541 G/L), which
deteriorated despite treatment. This time a TIPS revision with
an adequate lowering of porto-systemic pressure gradient was
not expected; therefore, a spleno-renal shunt was created in
order to treat the complications of portal hypertension (see
Figure 3A). However, within the course of the following weeks,
the patient developed several flares of ET with platelets around
800 G/L despite treatment. When renal dysfunction was present
as hepatorenal syndrome, she was listed for LTX 3 months later
(initial model for end-stage liver disease (MELD)-score 28 plus
special request for Non-Standard Exception [NSE]). Bone
marrow transplantation to cure ET was discussed; however,
the patient did not fulfill the criteria. During this time, the liver
function deteriorated, and magnetic resonance imaging revealed
a >7 cm measuring central ‘‘tumor,’’ which turned out to be a
necrotic BCS-nodule (see Figure 3B). An organ allocation for
LTX was finally achieved 19 months after delivery. Unfortu-
emonstrating patent TIPS perfusion. (B, C) Invasive TIPS-control
epatopetal flow after TIPS elongation: (1) main portal vein; (2) left
hunt.nonfunction (PNF) of the first graft, and despite double retrans-
plantation the patient succumbed 2 weeks later.DISCUSSION
With a prevalence of 1 in 100.000 to 500.000,7,8 primary
BCS is a rare disorder. Characterized by abdominal pain,
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. CT scan demonstrating stent in stent configuration
Medicine  Volume 95, Number 22, June 2016hepatomegaly, and ascites, the temporal dynamics, site, and
extent of obstruction determine its clinical course.2,9,10 Predis-
posing factors include, among others, inherited or acquired
hypercoagulability and especially myeloproliferative diseases,
as in our case.11 Pregnancy itself is also a risk factor for BCS;
however, usually additional risk factors are present.12 With a 3-
year-lethality of 90%, untreated BCS has a dismal prognosis.8
Due to the paucity of data, treatment is based on expert
consensus and consists of anticoagulation, interventional angio-
plasty, or TIPS stent with the aim to decompress the portal
venous compartment. If these treatments fail, LTX remains as
the last resort.1,7,10,13
and TIPS reocclusion. CT ¼ computed tomography, TIPS ¼ trans-
jugular portosystemic shunt.In addition to the pregnancy-induced hypercoagulability,
several changes inherent to pregnancy add to its detrimental
effect on BCS. These include blood volume expansion and
FIGURE 3. (A) CT scan demonstrating occluded TIPS (arrowhead)
with multiple regenerative nodules. (B) Axial T2-weighted fat-supp
nodules (arrows) and massive central liver fibrosis with edema (arrow
TIPS ¼ transjugular portosystemic shunt.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.hypoproteinemia; the rise in intraabdominal pressure; pressure
of the gravid uterus on the IVC and other intraabdominal
vessels, including the lymphatic system; and the displacement
of intraabdominal organs by the expanding uterus, causing
changes in their respective anatomical relationship.14–16 The
occurrence of thrombosis despite full-dose and aXa-adjusted
anticoagulant treatment underscores the high thrombotic risk of
ET patients during pregnancy.
Historical case series on BCS and pregnancy, reporting a 1-
year maternal mortality of 50%17 are not suitable for risk
assessment due to the advent of additional treatment modalities,
in particular TIPS.18–20 Contemporary reports on pregnancy in
BCS (from 1990 onwards) are restricted to 1 small series21 and 3
case reports.22–24 Details are listed in Table 1. Overall, 27
pregnancies in 19 women with pre-existing BCS are described.
Even though there was no maternal mortality during pregnancy,
delivery and follow-up, morbidity was considerable, including
thrombosis, hemorrhage, and TIPS occlusion. Likewise, fetal-
neonatal outcome was poor, with a high rate of pregnancy losses
and preterm births.
We cannot prove that the detrimental course of the disease
could have been avoided if the patient had abstained from
pregnancy. The long time intervals with stable disease and
the rapid downward trend during pregnancy and after delivery,
however, point to a relevant contribution of pregnancy to the
lethal course.
In women with pre-existing cardiac disease, a classifi-
cation has been developed, which is based on disease severity
and anticipated impact of pregnancy on the underlying con-
dition.25,26 It allows the attending physician risk assessment,
preconception counseling, and risk-adapted care during preg-
nancy and childbirth. In analogy, we suggest the classification
of BCS into World Health Organization (WHO) Classes I to IV
as follows:
Class 1: maternal mortality not increased; no or only slight
increase in maternal morbidity.
Class 2: maternal mortality slightly increased; maternal
morbidity moderately increased.
Class 3: maternal mortality significantly increased; severe
maternal morbidity. Interdisciplinary management before,
Pregnancy in BCSduring, and after pregnancy is mandatory.
Class 4: extremely high maternal mortality, high risk of
severe morbidity. Pregnancy is contraindicated, termination
, patent splenorenal shunt (arrow), and cirrhotic liver disease
ressed MR image demonstrating a cirrhotic liver with siderotic
head). CT ¼ computed tomography, MR ¼ magnetic resonance,
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prS
B
2
oegnancy, management as for class 3 is required.Allocation criteria may include the following:
General: age; time between diagnosis and pregnancy.(a)
(b) History: presence and type of prothrombotic factors;
number of thrombosed veins; complications of portal
hypertension; type and number of previous interventions.
Clinical findings: ascites, hepatosplenomegaly, esophageal(c)
varices; cholangiopathy.(d) Laboratory results: liver function, kidney function,
infection, coagulation.
Diagnostic imaging: IVC obstruction, collaterals.(e)
(f) Rotterdam, international prognostic score of thrombosis in
World Health Organization-essential thrombocythemia
(IPSET) or other scores.7,27
The usefulness of these and additional criteria, however,
needs to be established.7,27 With numbers of women with BCS
seeking pregnancy expected to rise, the scoring system may
help in preconception risk assessment and counseling; further-
more, it may support in the establishment of treatment algor-
ithms of BCS in pregnancy.
Notwithstanding that, a favorable outcome of pregnancy
in women with BCS requires an interdisciplinary team
of specialists in gastroenterology, radiology, visceral
surgery, hemostaseology, fetal medicine, obstetrics, and neo-
natology. More data are needed to adequately manage these
challenging cases.
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